Picture of SciClone Pharmaceuticals (Holdings) logo

6600 SciClone Pharmaceuticals (Holdings) Share Price

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeMid Cap

Momentum

Relative Strength (%)
1m+29.82%
3m+14.25%
6m+50.03%
1yr+37.72%
Volume Change (%)
10d/3m+46.04%
Price vs... (%)
52w High-0.37%
50d MA+28.1%
200d MA+43.08%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)8.28
PEG Ratio (f)0.74
EPS Growth (f)12.63%
Dividend Yield (f)1.49%
Valuation (ttm)IndustryMarket
Price to Book Value3.29
Price to Tang. Book3.99
Price to Free Cashflow8.88
Price to Sales3.22
EV to EBITDA6.5

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital32.44%
Return on Equity35.32%
Operating Margin36.77%

Financial Summary

Year End 31st DecUnit201820192020202120222023E2024ECAGR / Avg
Total RevenueCNYm1,408.871,708.071,918.562,518.472,749.683,125.23,575.1217.78%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+2627.85+14.88+59.94-2.67-5.39+18.57+12.63n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of SciClone Pharmaceuticals (Holdings) EPS forecast chart

Profile Summary

SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
May 13th, 2020
Public Since
March 3rd, 2021
No. of Employees
1,000
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
hk flag iconStock Exchange of Hong Kong Limited
Shares in Issue
627,296,632
Blurred out image of a map
Address
22/F, SHANGHAI
Web
https://www.sciclone.com/
Phone
Auditors
PricewaterhouseCoopers

6600 Share Price Performance

Upcoming Events for 6600

SciClone Pharmaceuticals (Holdings) Ltd Annual Shareholders Meeting

Similar to 6600

Picture of 3D Medicines logo

3D Medicines

hk flag iconStock Exchange of Hong Kong Limited

Picture of 3SBio logo

3SBio

hk flag iconStock Exchange of Hong Kong Limited

Picture of AIM Vaccine Co logo

AIM Vaccine Co

hk flag iconStock Exchange of Hong Kong Limited

Picture of Ascletis Pharma logo

Ascletis Pharma

hk flag iconStock Exchange of Hong Kong Limited

Picture of Asymchem Laboratories Tianjin Co logo

Asymchem Laboratories Tianjin Co

hk flag iconStock Exchange of Hong Kong Limited

FAQ